Biotech firm BioAge reports a Q1 GAAP loss of $0.52 per share as revenue reaches $2.8 million.
BioAge Labs reported a first-quarter GAAP loss of $0.52 per share, matching its revenue of $2.8 million for the period. The company’s financial results reflect ongoing investment in research and development amid early-stage operations.
As of March 31, 2026, BioAge held $384.9 million in cash, cash equivalents, and marketable securities. The company stated its current liquidity is sufficient to fund operations under its existing plan, though no specific timeline was provided.
Shares showed limited movement in after-hours trading following the release.